419 filings
Page 2 of 21
8-K
kruu7h50v3jp7
17 Apr 17
Repros Announces the Issuance of New U.S. Patent Relating to Treatment Using Off Drug Intervals For Certain Uterine Conditions
12:00am
8-K
ogzmshg73xoee
13 Apr 17
Departure of Directors or Certain Officers
12:00am
8-K
dbqxn0mjt6
10 Apr 17
Company Holds Meeting with FDA to Discuss Oral Proellex® in the Treatment of Uterine Fibroids
12:00am
8-K
t0by9ts4uw 0uq6j00vv
31 Mar 17
Repros Therapeutics Inc.® Reports Fourth Quarter and Year End 2016 Financial Results
12:00am
8-K
91idkllv
2 Feb 17
Departure of Directors or Certain Officers
12:00am
8-K
gbok9bcj
30 Jan 17
FDA Grants End of Phase 2 Meeting to Discuss Phase 3 Requirements for Oral Proellex® in the Treatment of Uterine Fibroids
12:00am
8-K
hn5ip9 9yvik
19 Dec 16
Repros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex® in the Treatment of Endometriosis
12:00am
8-K
ws32gejxsz fn
12 Dec 16
Repros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex® in the Treatment of Symptomatic Uterine Fibroids
12:00am
8-K
b7wut etad
7 Dec 16
Regulation FD Disclosure
12:00am
8-K
tkds5cuxfbz
15 Nov 16
Regulation FD Disclosure
12:00am
8-K
u4xseh
14 Nov 16
Regulation FD Disclosure
12:00am
8-K
0yg5lh5smgwxhnintp
8 Nov 16
Repros Therapeutics Inc.® Reports Third Quarter 2016 Financial Results
12:00am
8-K
rq3g dwvdzhxlt44stp
5 Oct 16
Repros Announces Acceptance of Dossier for Enclomiphene for Secondary Hypogonadism by European Authorities
12:00am
8-K
7rfaky499 eni
26 Sep 16
FDA Schedules Advisory Committee Meeting To Discuss Secondary Hypogonadism
12:00am
8-K
ss0521v6
12 Sep 16
Regulation FD Disclosure
12:00am
8-K
cpcvvoohpx
12 Sep 16
Repros Announces Submission of MAA to the European Medicines Agency for Enclomiphene in the Treatment of Secondary Hypogonadism
12:00am
8-K
o3l5km1hh3gt r7h
7 Sep 16
Repros Provides Phase 2 Results Showing Positive Outcomes for Oral Proellex® in Women With Moderate to Severe Endometriosis
12:00am
8-K
d6dcz58l5genrx67q
18 Aug 16
Regulation FD Disclosure
12:00am
8-K
jzgvj6z
15 Aug 16
Repros Provides Six Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men
12:00am
8-K
3hexw97t9 8mr2i1
9 Aug 16
Repros Therapeutics Inc.® Reports Second Quarter 2016 Financial Results
12:00am